Struggling small-cap med-tech company Accuray (ARAY)
continues to demonstrate why it's generally a bad idea to bother with
troubled companies that continually have to explain their
underperformance. Accuray has struggled to gain any traction on its much
larger rivals Varian (VAR)
and Elekta, and Thursday's big warning shows just how far this company
has yet to go to become a real rival. While bulls will likely argue that
the company is sweeping the deck and putting the worst behind it, I
think it's getting harder and harder to maintain a bullish thesis.
Please continue reading here:
Another Big Step Back For Accuray
No comments:
Post a Comment